Innovax has developed a unique “technology platform for recombinant (E. coli) virus-like particle vaccines” in cooperation with Xiamen University, breaking through the patent barriers of foreign companies and establishing corresponding independent intellectual property rights. Unlike the eukaryotic expression systems of yeast and insect cell baculovirus used by big foreign companies, this technology platform features low production cost, high efficiency, easy scale-up and high safety, and has the same immunogenicity as the virus-like particles vaccines developed with the eukaryotic expression system, achieving a perfect combination of cost, production efficiency and immune effect. This technology platform has great application prospects due to its good versatility which enables the platform to be applied to the development of vaccines against many different pathogens.